You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

29 Results
Guidelines and Advice
Status: Current
ID: 3-14
Version: 3
Jun 2025
Drug
Other Name(s): Temodal®
Aug 2025
Drug
Other Name(s): Adcetris®
Jun 2025
Drug
Other Name(s): Mekinist®
Jun 2025
Drug
Other Name(s): Blincyto®
Nov 2025
Regimen
Cancer Type:
Central Nervous System
Intent: Palliative
Funding:
ODB - General Benefit
    temozolomide
Aug 2025
Regimen
Intent: Palliative
Funding:
Exceptional Access Program
    trametinib - As monotherapy in patients with BRAF V600 mutation-positive unresectable or metastatic melanoma, according to specific criteria
Jun 2025
Regimen
Cancer Type:
Gynecologic, 
Ovary
Intent: Palliative
Jul 2025
Regimen
Cancer Type:
Hematologic, 
Leukemia - Acute Lymphoblastic (ALL)
Intent: Palliative
Funding:
New Drug Funding Program
    Blinatumomab - Relapsed or Refractory Acute Lymphoblastic Leukemia (Ph+ BCP-ALL)
New Drug Funding Program
    Blinatumomab - Relapsed or Refractory Acute Lymphoblastic Leukemia (Ph- BCP-ALL)
Sep 2025
Regimen
Cancer Type:
Central Nervous System
Intent: Adjuvant
Funding:
ODB - General Benefit
    temozolomide
Aug 2025
Regimen
Intent: Palliative
Funding:
ODB - General Benefit
    tamoxifen
Sep 2025

Pages